Skip to content

Prognostic Value of AIMS65 Score to Predict Outcome in Patients With Acute Upper Gastrointestinal Bleeding

Prognostic Value of AIMS65 Score to Predict Outcome in Patients With Acute Upper Gastrointestinal Bleeding

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05773339
Enrollment
100
Registered
2023-03-17
Start date
2023-03-01
Completion date
2023-09-30
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Acute Upper Gastrointestinal Bleeding

Brief summary

Prognostic Value of AIMS65 Score to predict outcome in patients with acute upper gastrointestinal bleeding

Detailed description

Gastrointestinal (GI) bleeding is one of the most important disease presentations in the emergency department. The course of the disease ranges from a self-limiting process to a life-threatening condition that requires emergency intervention. Evaluation of severity and the need for endoscopic hemostasis are matters of immediate decision. several prognostic scoring systems have been used to predict outcomes of upper GI bleeding ,such as the Rockall score, Glasgow-Blatchford score (GBS), and the AIMS65 score, among which AIMS65 is relatively easy to remember and simple to calculate by using parameters routinely available in the ED and importantly does not require endoscopic variables for calculation.. The AIMS65 score consists of five factors: (i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years). AIMS65 score \>1: high risk patients. AIMS65 score \>2: consider ICU management and an urgent endoscopy following adequate volume resuscitation, while AIMS65 score of 0 can be considered for outpatient management. AIMS65 score is a simple non-endoscopic risk score that can be applied in patients of acute upper gastrointestinal bleeding to risk stratify and to predict in-patient mortality, the need for blood transfusion, endoscopic therapy or ICU admission. In a comparative study of AIMS65 score and GBS ,they found that the AIMS65 score was superior in predicting inpatient mortality from UGIB, while the GBS was superior for predicting the need for blood transfusion. Both scores were similar in predicting the composite clinical endpoint .

Interventions

OTHERAIMS65 score

The AIMS65 score consists of five factors: (i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years).

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* o Patients above 18 years of age. * Patients with acute UGIB presenting within 24 hours of hemorrhage onset. * Endoscopic evaluation done after hospital admission.

Exclusion criteria

* o Patients denying for consent. * Patients with late presentation (\>24 hours) after UGIB onset.

Design outcomes

Primary

MeasureTime frameDescription
to evaluate the prognostic value of AIMS65 score in patients with upper gastrointestinal tract bleeding admitted to Sohag University Hospital.6 monthsblood transfusion endoscopic therapy ICU admission Need of surgery, incidence of rebleeding duration of hospital and ICU stay.

Countries

Egypt

Contacts

Primary Contactnessma M abbass, resident
nesmamahmoud@med.sohag.edu.eg01009692981
Backup ContactAli T Ali, professor
01005871047

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026